Literature DB >> 30201051

TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study.

Petrus J de Vries1, Elena Belousova2, Mirjana P Benedik3, Tom Carter4, Vincent Cottin5, Paolo Curatolo6, Maria Dahlin7, Lisa D'Amato8, Guillaume B d'Augères9, José C Ferreira10, Martha Feucht11, Carla Fladrowski12,13, Christoph Hertzberg14, Sergiusz Jozwiak15, J Chris Kingswood16, John A Lawson17, Alfons Macaya18, Ruben Marques8,19, Rima Nabbout20, Finbar O'Callaghan21, Jiong Qin22, Valentin Sander23, Matthias Sauter24, Seema Shah25, Yukitoshi Takahashi26, Renaud Touraine27, Sotiris Youroukos28, Bernard Zonnenberg29, Anna C Jansen30.   

Abstract

BACKGROUND: Most evidence for TSC-associated neuropsychiatric disorders (TAND) to date have come from small studies and case reports, and very little is known about TAND in adults. We explored baseline TAND data from the large-scale international TOSCA natural history study to compare childhood and adult patterns, describe age-based patterns, and explore genotype-TAND correlations.
RESULTS: The study enrolled 2216 eligible participants with TSC from 170 sites across 31 countries at the data cut-off for the third interim analysis (data cut-off date: September 30, 2015). The most common behavioural problems (reported in > 10% of participants) were overactivity, sleep difficulties, impulsivity, anxiety, mood swings, severe aggression, depressed mood, self-injury, and obsessions. Psychiatric disorders included autism spectrum disorder (ASD, 21.1%), attention deficit hyperactivity disorder (ADHD, 19.1%), anxiety disorder (9.7%), and depressive disorder (6.1%). Intelligence quotient (IQ) scores were available for 885 participants. Of these, 44.4% had normal IQ, while mild, moderate, severe, and profound degrees of intellectual disability (ID) were observed in 28.1, 15.1, 9.3, and 3.1%, respectively. Academic difficulties were identified in 58.6% of participants, and neuropsychological deficits (performance <5th percentile) in 55.7%. Significantly higher rates of overactivity and impulsivity were observed in children and higher rates of anxiety, depressed mood, mood swings, obsessions, psychosis and hallucinations were observed in adults. Genotype-TAND correlations showed a higher frequency of self-injury, ASD, academic difficulties and neuropsychological deficits in TSC2. Those with no mutations identified (NMI) showed a mixed pattern of TAND manifestations. Children and those with TSC2 had significantly higher rates of intellectual disability, suggesting that age and genotype comparisons should be interpreted with caution.
CONCLUSIONS: These results emphasize the magnitude of TAND in TSC and the importance of evaluating for neuropsychiatric comorbidity in all children and adults with TSC, across TSC1 and TSC2 genotypes, as well as in those with no mutations identified. However, the high rates of unreported or missing TAND data in this study underline the fact that, even in expert centres, TAND remains underdiagnosed and potentially undertreated.

Entities:  

Keywords:  TOSCA; TSC-associated neuropsychiatric disorders; Tuberous sclerosis complex

Mesh:

Substances:

Year:  2018        PMID: 30201051      PMCID: PMC6131901          DOI: 10.1186/s13023-018-0901-8

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


Background

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by the formation of hamartomas in multiple organ systems with a wide diversity of symptoms and severity across individuals [1, 2]. The majority of individuals with TSC have central nervous system involvement with a wide range of structural manifestations, such as cortical tubers, subependymal nodules, and aberrations of gray and white matter as well as high rates of functional manifestations, such as epilepsy, intellectual disability (ID), and behavioural problems [3-5]. The neurological, neuropsychiatric, and renal manifestations represent the greatest burden of disease of all TSC-related manifestations [3]. TSC-associated neuropsychiatric disorders (TAND) is an umbrella term coined by the Neuropsychiatry Panel of the 2012 International Consensus Conference for TSC, and encompasses a range of neuropsychiatric manifestations across various levels of investigation [2, 3, 5]. These include the behavioural level (observed behaviours such as sleep problems or aggressive behaviours), the psychiatric level (DSM/ICD defined psychiatric disorders such as autism spectrum disorders [ASD] or attention deficit hyperactivity disorder [ADHD]), the intellectual level (intellectual ability as defined by intelligence quotient [IQ]-type tests), the academic level (learning disorders, e.g., reading or mathematics difficulties), and the psychosocial level (e.g., self-esteem, family difficulties) [3, 5, 6]. TAND represent a significant burden of disease and have a major impact on quality of life of individuals with TSC and their families, given their impact on education, employment, and social life of patients and their family [3, 5]. The rate and pattern of TAND vary greatly among patients with TSC [3, 5, 7–11]. Overall, about 90% of individuals with TSC exhibit TAND features to some extent during their lifetime, with ASD and ID reported in up to 50% of individuals [3, 5, 6]. Results show differential rates in those with and without ID [12]. However, even individuals with normal intellectual abilities are at risk of developing TAND manifestations, particularly in the academic, neuropsychological, and psychosocial domains [8]. Despite the high rates of TAND, a 2010 survey of members of the Tuberous Sclerosis Association in the United Kingdom indicated that only 20% of individuals with TSC had ever received any assessment or treatment for TAND, suggesting a large assessment and treatment gap [5, 6, 12, 13]. It is important to acknowledge that the majority of evidence for rates and patterns of TAND to date have come from relatively small studies and case reports. The largest published studies to date have included a few hundred participants [10, 12, 14]. Furthermore, very little TAND data are available about adults with TSC [15] or about the age-based pattern of TAND. The underlying aetiology of TAND is likely to be combinatorial and multifactorial [16]. There is evidence that the genetic aberrations of TSC may be sufficient to cause TAND manifestations, [16, 17] with combinatorial and interactive contribution from functional and structural factors [16-22]. Individuals with TSC2 mutations have been reported to have a greater likelihood of ID than those with TSC1, [23-26] but both TSC1 and TSC2 mutations have been associated with the full range of intellectual ability from high IQ to profound ID [25, 26]. Individuals with no mutation identified (NMI) after genetic testing have typically been described to have ID profiles between those with TSC1 and TSC2 [23-26]. These studies have also been based on relatively small samples and no study to date has examined other aspects of TAND in relation to genotype. The largest natural history study of TSC to date – the TOSCA (TuberOus SClerosis registry to increase disease Awareness) study is a multi-centre, international disease registry designed with the aim of providing deeper insights into the manifestations of TSC and its management [27, 28]. In a previous publication outlining baseline findings from the TOSCA cohort of 2093 individuals, we presented topline findings of TAND features in the largest TSC cohort reported globally to date [28]. Results showed that ID was observed in 54% of the evaluated participants and suggested that psychiatric disorders were typically diagnosed late. We also identified significant non-reported or missing data, which suggested that even in expert TSC centres around the globe, TAND may be underdiagnosed and therefore under-treated [28]. Here, we performed a detailed exploration of the largest TAND dataset to date using TOSCA baseline data of all the patients enrolled at the cut-off of September 30, 2015, with the specific aim of comparing childhood and adult TAND profiles, describing the age-related pattern of TAND, and examining TAND in relation to genotype.

Methods

A detailed description of the methods of the TOSCA registry has been provided previously [27]. In short, individuals of any age with a documented visit for TSC before 12 months of enrollment or newly diagnosed with TSC were included in the study between August 2012 and August 2014. Information on participant demography, family history, genotype, vital signs, prenatal history, clinical features of TSC across all organ systems, comorbidities, and rare manifestations were collected, both retrospectively and prospectively at baseline and annually thereafter for up to 5 years. Given that this was a natural history study, participants were followed up based on clinical need, and no clinical, laboratory or formal TAND evaluations were mandated by the protocol. The terms and operationalization of TAND manifestations and ‘levels’ were defined as in the primary TAND publication [5]. The TOSCA registry was designed and conducted in accordance with the Guidelines for Good Clinical Practice and ethical principles outlined in the Declaration of Helsinki [29, 30]. Written informed consent, with prior endorsement by all local institutional review boards (human research ethics committees) was obtained from all participants, parents, or guardians prior to registry enrollment. For the purposes of this manuscript, descriptive statistics were used to summarize TAND data. Frequency of TAND features were extracted and presented as percentage of individuals with available data (excluding non-reported or missing data). Intellectual ability was categorized as normal (IQ > 70), mild ID (IQ 51–70), moderate ID (IQ 36–50), severe ID (IQ 20–35), and profound ID (IQ < 20), according to DSM-5/ICD-10 [31, 32]. Psychiatric disorders were defined according to the DSM-5/ICD-10. Age-based patterns of TAND (children vs adults) and the association between TAND and genotype (TSC1 vs TSC2) were analyzed using Chi-square test. The TOSCA study included data collection on all levels of TAND as outlined above and summarised in the primary TAND manuscript [5], apart from psychosocial characteristics, such as self-esteem, sibling, or family stressors, which were only included after the TOSCA database was set up.

Results

A total of 2216 participants (1154 females and 1062 males) with TSC were enrolled into the TOSCA registry from 170 sites across 31 countries at the data cut-off for the third interim analysis (September 30, 2015). The median age of the TOSCA cohort was 13 years (range, < 1–71) with 1410 individuals (63.6%) aged ≤18 years.

Overall TAND features

Table 1 and Fig. 1 represent the frequencies of TAND features in the overall TOSCA cohort.
Table 1

TAND Features in the Overall TOSCA Cohort (N = 2216)

TAND FeaturesIndividuals With Manifestation, n (%)aIndividuals With Available Data, n (%)Individuals with Data Not Available*, n (%)
Behavioural level
 Overactivity337 (45.0)749 (33.8)1467 (66.2)
 Sleep difficulties331 (43.9)754 (34.0)1462 (66.0)
 Impulsivity317 (42.7)742 (33.5)1474 (66.5)
 Anxiety240 (33.3)720 (32.5)1496 (67.5)
 Mood swings214 (29.8)718 (32.4)1498 (67.6)
 Severe aggression183 (24.3)754 (34.0)1462 (66.0)
 Depression mood139 (19.2)724 (32.7)1492 (67.3)
 Self-injury117 (15.5)755 (34.1)1461 (65.9)
 Obsessions100 (14.0)714 (32.2)1502 (67.8)
 Psychosis40 (5.5)725 (32.7)1491 (67.3)
 Hallucinations26 (3.6)719 (32.5)1497 (67.5)
Psychiatric level
 ASD314 (21.1)1486 (67.1)730 (32.9)
 ADHD268 (19.1)1404 (63.4)812 (36.6)
 Anxiety disorder133 (9.7)1365 (61.6)851 (38.4)
 Depressive disorder84 (6.1)1371 (61.9)845 (38.1)
Intellectual level
 Normal393 (44.4)885 (39.9)1331 (60.1)
 Mild ID249 (28.1)885 (39.9)1331 (60.1)
 Moderate ID134 (15.1)885 (39.9)1331 (60.1)
 Severe ID82 (9.3)885 (39.9)1331 (60.1)
 Profound ID27 (3.1)885 (39.9)1331 (60.1)
Academic level
 Individuals ever had difficulties in academic performance735 (58.6)1254 (56.6)962 (43.4)
 Individuals assessed for academic difficulties359 (48.8)bNANA
Neuropsychological level
 Individuals ever had any neuropsychological skill assessed564 (41.6)1355 (61.1)861 (38.9)
 Individuals with performance <5th percentile314 (55.7)cNANA

ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, NA not applicable, TAND TSC-associated neuropsychiatric disorders

*Missing data includes unknown option ticked for TAND features in eCRF by patient/investigator

aPercentages calculated considering only available data and excluding missing data unless otherwise specified

bPercentages calculated based on the number of individuals with reported academic difficulties as denominator

cPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator

Fig. 1

Summary of TAND Findings from the TOSCA Study (N = 2216)

TAND Features in the Overall TOSCA Cohort (N = 2216) ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, NA not applicable, TAND TSC-associated neuropsychiatric disorders *Missing data includes unknown option ticked for TAND features in eCRF by patient/investigator aPercentages calculated considering only available data and excluding missing data unless otherwise specified bPercentages calculated based on the number of individuals with reported academic difficulties as denominator cPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator Summary of TAND Findings from the TOSCA Study (N = 2216)

Behavioural level

The most common behavioural problems (reported in > 10% of participants) were overactivity (45%), sleep difficulties (43.9%), impulsivity (42.7%), anxiety (33.3%), mood swings (29.8%), severe aggression (24.3%), depressed mood (19.2%), self-injury (15.5%), and obsessions (14%).

Psychiatric level

ASD was reported in 21.1% (314/1486), ADHD in 19.1% (268/1404), anxiety disorder in 9.7% (133/1365), depressive disorder in 6.1% (84/1371), and “other” psychiatric disorders were reported in 8.4% (115/1377) of participants. The median age at diagnosis of neuropsychiatric disorders were 5 years for ASD (mean, 7.8 years; range, < 1–40), 6 years for ADHD (mean, 7.8 years; range, < 1–38), 13.5 for anxiety disorder (mean, 17.4 years; range, < 1–50), 21 years for depressive disorder (mean, 24.3 years; range, 3–49), and 11 years for “other” psychiatric disorders (mean, 14.1 years; range, < 1–59).

Intellectual level

An IQ assessment was available for 885 participants (39.9%). Of these, 393 participants (44.4%) had normal intellectual ability, while mild, moderate, severe, and profound degrees of ID were observed in 28.1% (249/885), 15.1% (134/885), 9.3% (82/885), and 3.1% (27/885), respectively.

Academic and neuropsychological levels

Academic/scholastic difficulties, classified as learning disorders in DSM-5, such as mathematics, reading, writing, or spelling, were noted in 58.6% (735/1254) of participants. Neuropsychological skills were formally assessed in 41.6% (564/1355) of participants, and neuropsychological deficits (performance <5th percentile) were identified in 55.7% (314/564) of those evaluated.

TAND features in children vs adults

Some differences were observed in the frequencies of TAND features between children (aged ≤18 years), and adults (aged > 18 years) (Table 2). At the behavioural level, the rates of overactivity and impulsivity were significantly higher for children than adults (54.8% vs 21.4% and 46.7% vs 33.2% respectively, p < 0.001), while rates of anxiety, mood swings, depressed mood, obsessions, psychosis and hallucinations were significantly higher in adults than children (50.9% vs 25.8%; 40.8% vs 25.2%; 43.9% vs 8.2%; 19.2% vs 11.8%; 11.3% vs 3%; 10.3% vs 0.6%, respectively, P < 0.001 for all except obsessions, P < 0.01). Interestingly, some behavioural manifestations showed similar rates in children and adults. For instance, sleep difficulties and severe aggression were very similar between children and adults (Table 2). At the psychiatric level, ASD and ADHD were reported at higher rates in children than in adults (23.1% vs 16.1%; 22.4% vs 10.5%; p = 0.0029 and P < 0.001 respectively), while rates of anxiety disorder and depressive disorder were higher in adults than in children (16.8% vs 7%; 16.3% vs 2.1% respectively; P < 0.001). We observed no major differences in the rates of academic difficulties and neuropsychological skills between children and adults (Table 2). However, highly significant difference was observed between the rates of intellectual disability between children and adults (Table 2).
Table 2

TAND Features in Children vs Adults

TAND FeaturesChildren (≤ 18 Years) With Manifestation, (n = 1410)n (%)Adults (>  18 Years) With Manifestation, (n = 806)n (%)p value
Behavioural levela
 Overactivity290 (54.8)47 (21.4)< 0.0001
 Sleep difficulties225 (43.4)106 (45.1)0.6531
 Impulsivity244 (46.7)73 (33.2)0.0006
 Anxiety130 (25.8)110 (50.9)< 0.0001
 Mood swings128 (25.2)86 (40.8)< 0.0001
 Severe aggression121 (22.9)62 (27.4)0.1850
 Depressed mood41 (8.2)98 (43.9)< 0.0001
 Self-injury73 (13.9)44 (19.2)0.0625
 Obsessions59 (11.8)41 (19.2)0.0085
 Psychosis15 (3.0)25 (11.3)< 0.0001
 Hallucinations3 (0.6)23 (10.3)< 0.0001
Psychiatric levela
 ASD246 (23.1)68 (16.1)0.0029
 ADHD227 (22.4)41 (10.5)< 0.0001
 Anxiety disorder68 (7)65 (16.8)< 0.0001
 Depressive disorder21 (2.1)63 (16.3)< 0.0001
Intellectual levelb
 Normal IQ283 (43.5)110 (47.0)
 Mild ID202 (31)47 (20.1)
 Moderate ID101 (15.5)33 (14.1)0.0005e
 Severe ID51 (7.8)31 (13.2)
 Profound ID14 (2.2)13 (5.6)
Academic level
 Individuals ever had difficulties in academic performancea506 (60.5)229 (54.8)0.0517
 Individuals assessed for academic difficultiesc273 (54.0)c86 (37.6)c0.0785
Neuropsychological level
 Individuals ever had any neuropsychological skill assesseda414 (42.5)150 (39.4)0.2926
 Individuals with performance <5th percentiled235 (56.8)d79 (52.7)d0.5333

ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, TAND TSC-associated neuropsychiatric disorders

aPercentages calculated considering only available data and excluding missing data unless otherwise specified

bPercentages calculated based on the number of individuals with IQ assessment available in each age group: ≤ 18 years, n = 585; > 18, n = 234)

cPercentages calculated based on the number of individuals with reported academic difficulties as denominator

dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator

eChi-square test showing association between children and adults across all levels of IQ

TAND Features in Children vs Adults ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, TAND TSC-associated neuropsychiatric disorders aPercentages calculated considering only available data and excluding missing data unless otherwise specified bPercentages calculated based on the number of individuals with IQ assessment available in each age group: ≤ 18 years, n = 585; > 18, n = 234) cPercentages calculated based on the number of individuals with reported academic difficulties as denominator dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator eChi-square test showing association between children and adults across all levels of IQ

TAND features by age bands

Frequencies of all the TAND features by age bands at consent are depicted in Table 3. The majority of TAND behavioural characteristics showed varying frequencies across age bands, but anxiety and depressed mood showed a clear pattern of increased frequency across increasing age bands. Interestingly, the rates of diagnoses of anxiety and depressive disorder showed a pattern that was not entirely consistent with the behavioural observations for anxiety and depressed mood. Severe and profound ID was reported at low rates in the youngest age group (3%), increasing in the under 10-year olds (6.6 and 9.7%), and ranging between 12.7–19.3% in the older age bands.
Table 3

TAND Features According to Age Bands (Based on Age at Consent)

TAND FeaturesAge at Registry Consent, Years
≤ 2>  2to ≤ 5>  5 to ≤ 9>  9 to ≤ 14>  14 to ≤ 18>  18 to ≤ 40>  40
n = 283n = 301n = 335n = 307n = 184n = 579n = 227
Behavioural levela
 Overactivity21 (53.8)77 (65.3)94 (60.6)67 (47.5)31 (40.8)41 (23.7)6 (12.8)
 Sleep difficulties24 (64.9)43 (38.4)61 (40.7)68 (48.6)29 (36.3)70 (38.5)36 (67.9)
 Impulsivity12 (31.6)54 (47.4)79 (52.0)70 (49.3)29 (38.2)67 (38.3)6 (13.3)
 Anxiety2 (5.6)24 (21.2)33 (22.9)45 (33.3)26 (34.2)74 (44.6)36 (72)
 Mood swings5 (13.5)18 (16.1)39 (25.8)36 (27.1)30 (40.5)77 (46.4)9 (20)
 Severe aggression2 (5.4)15 (13.0)45 (29.2)40 (27.8)19 (24.4)57 (31.7)5 (10.9)
 Depression mood0010 (6.9)17 (12.7)14 (18.7)68 (40.2)30 (55.6)
 Self-injury3 (7.9)9 (7.8)28 (18.7)23 (16.1)10 (12.7)37 (20.6)7 (14.3)
 Obsessions2 (5.6)7 (6.3)15 (10.3)22 (16.3)13 (17.6)33 (19.9)8 (17.0)
 Psychosis02 (1.8)4 (2.8)7 (5.2)2 (2.6)22 (12.6)3 (6.3)
 Hallucinations0003 (2.3)021 (11.9)2 (4.3)
Psychiatric levela
 ASD18 (10.8)49 (22.9)73 (26.2)68 (26.3)38 (26)65 (18.6)3 (4.2)
 ADHD11 (7.1)50 (24.2)82 (31.1)61 (24.5)23 (16.7)39 (12.1)2 (2.9)
 Anxiety disorder1 (0.6)8 (3.9)15 (5.9)31 (13.1)13 (10.4)51 (16.1)14 (19.7)
 Depressive disorder03 (1.4)2 (0.8)8 (3.4)8 (6.3)44 (14.2)19 (25)
Intellectual levelb
 Normal IQ37 (56.1)72 (52.9)74 (39.8)64 (37.9)36 (38.3)82 (42.7)28 (66.7)
 Mild ID18 (27.3)38 (27.9)58 (31.2)56 (33.1)32 (34.0)43 (22.4)4 (9.5)
 Moderate ID9 (13.6)17 (12.5)36 (19.4)25 (14.8)14 (14.9)30 (15.6)3 (7.1)
 Severe ID1 (1.5)9 (6.6)13 (7.0)18 (10.7)10 (10.6)27 (14.1)4 (9.5)
 Profound ID1 (1.5)05 (2.7)6 (3.6)2 (2.1)10 (5.2)3 (7.1)
Academic level
 Individuals ever had difficulties in academic performancea1 (1.3)48 (36.9)167 (69.3)193 (75.7)97 (73.5)195 (59.6)34 (37.4)
 Individuals assessed for academic difficultiesc020 (41.7)93 (55.7)103 (53.4)57 (58.8)77 (39.5)9 (26.5)
Neuropsychological level
 Individuals ever had any neuropsychological skill assesseda31 (20.4)69 (32.4)121 (48.2)124 (53.2)69 (55.2)129 (42.7)21 (26.6)
 Individuals with performance <5th percentiled12 (38.7)35 (50.7)69 (57.0)78 (62.9)41 (59.4)72 (55.8)7 (33.3)

ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, IQ intelligence quotient, ID intellectual disability, TAND TSC-associated neuropsychiatric disorders. Values are expressed as n (%)

aPercentages calculated considering only available data and excluding missing data

bPercentages calculated considering individuals with IQ assessment available in each age group: ≤ 2 years (n = 66); > 2 to ≤5 years (n = 136); > 5 to ≤9 (n = 186); > 9 to ≤14 (n = 169); > 14 to ≤18 (n = 94); > 18 to ≤40 (n = 192); > 40 (n = 42)

cPercentages calculated based on the number of individuals with reported academic difficulties as denominator

dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator

TAND Features According to Age Bands (Based on Age at Consent) ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, IQ intelligence quotient, ID intellectual disability, TAND TSC-associated neuropsychiatric disorders. Values are expressed as n (%) aPercentages calculated considering only available data and excluding missing data bPercentages calculated considering individuals with IQ assessment available in each age group: ≤ 2 years (n = 66); > 2 to ≤5 years (n = 136); > 5 to ≤9 (n = 186); > 9 to ≤14 (n = 169); > 14 to ≤18 (n = 94); > 18 to ≤40 (n = 192); > 40 (n = 42) cPercentages calculated based on the number of individuals with reported academic difficulties as denominator dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator

TAND and genotype

Molecular testing for genetic mutations was performed in 1000 participants (45.1%). Of them, 197 had TSC1 mutations, 644 had TSC2 mutations, and 144 had no mutation identified (NMI). At the behavioural level, TSC2 mutations were associated only with significantly higher frequency than TSC1 for self-injury (15.8% vs 6.3%, P = 0.0288; Table 4). At the psychiatric level, ASD was observed at significantly higher frequency in participants with TSC2 than those with TSC1 mutations (28.6% vs 12.2%, P < 0.001). ADHD, anxiety disorder and depressive disorder were not significantly different between the two genotypes, but it was interesting to observe that all three showed higher absolute frequencies in association with TSC1 rather than TSC2 (ADHD TSC1 = 17.6%; TSC2 = 16%, P = 0.6881; Anxiety disorder TSC1 = 10.1%; TSC2 = 8.6%; P = 0.7809; Depressive disorders TSC1 = 10%; TSC2 = 5.2%; P = 0.0509) (Table 4). The frequencies in behavioural and psychiatric manifestations of individuals with NMI ranged sometimes between and sometimes higher or lower than TSC1 and TSC2 (Table 4).
Table 4

TAND Features by Genotype*

TAND FeaturesIndividuals With TSC1 Mutation(n = 197)n (%)aIndividuals With TSC2 Mutation,(n = 644)n (%)aIndividuals With no TSC Mutation Identified (NMI),(n = 144)n (%)aStatistical difference between TSC1 and TSC2p Valuee
Behavioural level
 Overactivity27 (40.9)112 (43.4)24 (45.3)0.8788
 Sleep difficulties31 (48.4)129 (50.6)30 (54.5)0.5656
 Impulsivity32 (49.2)107 (41.6)23 (45.1)0.1773
 Anxiety24 (38.7)82 (33.6)17 (34.0)0.5519
 Mood swings14 (21.5)64 (26.6)15 (29.4)0.4907
 Severe aggression14 (21.2)56 (21.5)11 (20.8)0.9290
 Depression mood15 (24.2)46 (18.7)12 (23.5)0.2651
 Self-injury4 (6.3)41 (15.8)8 (14.5)0.0288
 Obsessions8 (13.1)35 (14.2)8 (16.0)0.9140
 Hallucinations3 (4.8)7 (2.8)2 (3.9)0.3960
 Psychosis4 (6.5)9 (3.6)3 (5.8)0.2865
Psychiatric level
 ASD18 (12.2)138 (28.6)17 (17.5)< 0.0001
 ADHD24 (17.6)72 (16.0)14 (14.9)0.6881
 Anxiety disorder14 (10.1)38 (8.6)8 (9.2)0.7809
 Depressive disorder14 (10.0)23 (5.2)7 (8.0)0.0509
Intellectual levelb
 Normal IQ62 (66.7)123 (42.0)41 (64.1)
 Mild ID15 (16.1)75 (25.6)14 (21.9)
 Moderate ID11 (11.8)57 (19.5)3 (4.7)0.001f
 Severe ID5 (5.4)30 (10.2)6 (9.4)
 Profound ID08 (2.7)0
Academic level
 Individuals ever had difficulties in academic performance63 (49.2)240 (63.5)53 (58.2)0.0051
 Individuals assessed for academic difficulties34 (54.0)c132 (55.0)c25 (47.2)c0.5391
Neuropsychological level
 Individuals ever had any neuropsychological skill assessed67 (51.1)216 (49.4)46 (51.1)0.7697
 Individuals with performance <5th percentile26 (38.8)d136 (63.0)d19 (41.3)d0.0024

ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, TAND TSC-associated neuropsychiatric disorders

*Molecular testing for genetic mutations was performed in 1000 (45.1%) individuals. Of these, 644 (64.4%) had a TSC2 gene mutation, 197 (19.7%) had a TSC1 gene mutation, 6 had both TSC1 and TSC2 gene mutations and 144 (14.4%) had no mutations. Data were not available for 9 individuals

aPercentages calculated considering only available data and excluding missing data unless otherwise specified

bPercentages calculated considering individuals with IQ assessment available in each group: Individuals with TSC1 mutation, n = 93; individuals with TSC2 mutation, n = 293)

cPercentages calculated based on the number of individuals with reported academic difficulties as denominator

dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator

eTSC1 vs TSC2

fChi-square test showing association between children and adults across all levels of IQ

TAND Features by Genotype* ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, TAND TSC-associated neuropsychiatric disorders *Molecular testing for genetic mutations was performed in 1000 (45.1%) individuals. Of these, 644 (64.4%) had a TSC2 gene mutation, 197 (19.7%) had a TSC1 gene mutation, 6 had both TSC1 and TSC2 gene mutations and 144 (14.4%) had no mutations. Data were not available for 9 individuals aPercentages calculated considering only available data and excluding missing data unless otherwise specified bPercentages calculated considering individuals with IQ assessment available in each group: Individuals with TSC1 mutation, n = 93; individuals with TSC2 mutation, n = 293) cPercentages calculated based on the number of individuals with reported academic difficulties as denominator dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator eTSC1 vs TSC2 fChi-square test showing association between children and adults across all levels of IQ Of the 93 participants with TSC1 mutation who had been evaluated using IQ-type tests, 62 (66.7%) had normal intellectual ability, 15 (16.1%) had mild ID, 11 (11.8%) had moderate ID, 5 (5.4%) had severe ID, and no participant had profound ID. Among 293 participants with TSC2 mutation who had been evaluated using IQ-type tests, 123 (42%) had normal intellectual ability, 75 (25.6%) had mild ID, 57 (19.5%) had moderate ID, 30 (10.2%) had severe ID, and 8 (2.7%) had profound ID. Significant difference was observed between TSC1 and TSC2 groups for IQ levels/categories. (P = 0.001, Table 4). Academic/scholastic difficulties were more common in individuals with TSC2 mutation than those with TSC1 mutation (63.5% vs 49.2%; P = 0.0051, Table 4). More individuals with TSC2 mutation had neuropsychological performance scores falling below the 5th percentile compared to those with TSC1 mutation (63% vs 38.8%, P = 0.0024). Individuals with NMI showed IQ, academic and neuropsychological profiles in between the frequencies of the group with TSC1 and TSC2.

Discussion

The TOSCA registry allowed exploration of the frequency of a wide range of TAND features in the largest cohort of TSC reported to date. We set out to examine the overall TAND profile, to compare childhood and adult patterns, age-based patterns, and genotype-TAND correlations. Results showed lower rates of behavioural and psychiatric disorders than previously reported, but similar rates of ID [3, 6, 8, 12]. The very high rates of non-reported or missing data in this study (in excess of 60% for behavioural and intellectual levels) may, at least in part, have contributed to the lower rates observed. The rates of academic difficulties and neuropsychological deficits, reported in this study for the first time, were very high and suggested that between half and two-thirds of individuals with TSC will have difficulties in these two TAND levels. In spite of relatively similar rates of ID between children and adults, we observed a pattern of higher overactivity and impulsivity in children, and higher rates of anxiety and depressed mood in adults. Interestingly, some TAND characteristics such as sleep problems and severe aggression remained high across all age bands, suggesting persistence of these difficulties across the lifespan. With regards to genotype-TAND correlations, we observed a genotype-intellectual phenotype correlation and a higher frequency of ASD in association with TSC2, similar to previous reports [8, 26]. Interestingly, fewer other TAND-genotype correlations were observed. Self-injury, ASD, academic difficulties and neuropsychological deficits were the only other significant correlations with TSC2. Given that all of these are known to be strongly correlated with intellectual level [12], and given the differences observed here in IQ groups, these results have to be treated with caution and should be explored in relation to matched or stratified IQ groups in future studies. We also observed a potential pattern of more depressed and anxious mood, and higher rates of anxiety and depressive disorders in association with TSC1 mutations. This was a novel observation not previously reported in the literature, but the same caveat in relation to IQ as potential confounder requires exploration in future studies. The TAND profile of individuals with NMI was also a novel finding. Intellectual, academic and neuropsychological profiles seemed to fall between the frequencies of those with TSC1 and TSC2 mutations, mapping onto intellectual findings previously reported [8, 26]. However, the same pattern was not seen in behavioural and psychiatric manifestations. About 7% of individuals in the general population are expected to have clinically significant behavioural problems [33]. However, much higher rates of behavioural difficulties are reported in patients with TSC [7]. In a pilot validation study of the TAND checklist, all the participants (n = 62) had reported at least one lifetime TAND behavioural difficulty, 97% had ≥2 behavioural difficulties and 89% reported ≥6 behavioural difficulties [6]. The findings in this large-scale international study confirm the high rates of a wide range of behavioural problems in TSC. The comparison between children and adults showed a pattern of lower overactive/impulsive behaviours in adults but higher anxiety or depressed mood. These findings map well onto typical age-based expectations in psychopathology [8, 9, 12]. However, our results also highlighted the fact that behavioural difficulties occurred across all ages in individuals with TSC. These findings underline the importance of expecting and evaluating for a changing profile of TAND difficulties from childhood into adulthood, as recommended in TAND assessment guidelines [2, 34, 35]. Among the psychiatric problems associated with TSC, ASD, and ADHD are the most common neurodevelopmental disorders in children, and anxiety/mood disorders the most common in adults [8]. The variable rates of ASD (17–68%) and ADHD (30–60%) reported in earlier studies can be understood based on different study methodologies, diagnostic criteria used, and level of intellectual ability of participants [7, 8, 36]. In this study, ASD and ADHD were reported in 21.1% and 19.1% of participants, respectively. As highlighted in our baseline paper [27] the diagnosis of ASD, in particular, was made very late (mean age, 7.8 years; median age, 5 years; range, 0–38 years) [28]. In spite of very high rates of anxiety and depressed mood symptoms in the cohort, the rates of diagnoses of anxiety disorders or depressive disorders were surprisingly low in our study (anxiety disorder, 9.7%; depressive disorder, 6.1%). Taking together the high rates of non-reported or missing data, late ages of diagnoses and frequencies observed in our cohort, we suggest that psychiatric disorders are underdiagnosed and potentially diagnosed late in individuals with TSC. The low rates of ASD and ADHD observed in adults here, may suggest a cohort effect where adults were not assessed for developmental disorders in the past decades. In line with previous reports, [8, 26, 37] the TOSCA registry showed a genotype-intellectual phenotype pattern suggesting a greater likelihood of ID in participants with TSC2 than those with TSC1 mutations. However, it was also important to note that only 66.7% of those with TSC1 had normal intellectual ability, suggesting that a third of individuals with TSC1 may have ID. Similarly, even though TSC2 mutations were more likely to be associated with ID, 42% of all individuals with TSC2 mutations had normal intellectual ability. Our findings therefore reinforce the message that genotype (TSC1 vs TSC2) is not a clinically helpful predictor of intellectual ability at an individual level [26]. The differences between those with TSC1 and TSC2 mutations observed in other aspects of TAND were of interest, particularly as all previous genotype-phenotype studies have suggested a more “severe” phenotype associated with TSC2 [38]. The possibility that specific aspects of TAND may be more likely in association with TSC1 is therefore a potentially important observation. We acknowledge that a TSC1 vs TSC2 differentiation may be highly oversimplistic, given that specific TSC mutations may be associated with very different functional consequences at a biochemical level [16, 26]. The challenge around unreported and missing TAND data in this study was significant. Fewer than 40% of behavioural data were available and only 39.9% of participants in the TOSCA registry received an evaluation of their intellectual ability. The overall rates of ID were consistent with previous studies, [8, 12] but we did not observe a bimodal distribution of intellectual ability as previously reported [23, 25, 39, 40]. Given that only about half of the TOSCA cohort received a formal evaluation for IQ, it is possible that more severely impaired individuals may not have been referred for an assessment of their intellectual or developmental quotient (as was done in the population-based study that observed the clear bimodal pattern) [39]. Academic data were not reported or were missing in 43.4% of the cohort and 38.9% were not reported or were missing regarding neuropsychological skills. Only 48.8% of those with academic difficulties ever received evaluations, and only 41.6% were evaluated for neuropsychological deficits. Whilst the very high rates of academic and neuropsychological deficits in TSC were a novel finding in the TOSCA registry and underlines the recommendation that all children with TSC should receive evaluation of their academic and neuropsychological needs, [2, 35] the very low proportion assessed raises significant clinical concern.

Conclusions

Together, findings from the TOSCA registry emphasize the magnitude of neuropsychiatric disorders in TSC, which has an enormous impact on quality of life of individuals with TSC and their families. However, there was a high proportion of non-reported or missing data, which may have impacted the overall findings of the study. Due to the observational nature of the registry, only data already available from clinical practice were collected. Moreover, considering the disease complexity and the fact that individuals with TSC were not always followed for all disease manifestations by the site involved in the registry, ensuring report of all disease manifestations of each participant was a major challenge. We therefore acknowledge the potential ascertainment biases that may come with large-scale clinic-based natural history studies such as this one. There is clearly a highly dynamic interaction between development, genotype, intellectual ability, epilepsy, anti-epilepsy and other pharmacological treatments, and environment in TSC. Future studies should therefore aim to examine these interrelations in an integrated way using suitable multilevel computational modelling. We also acknowledge that further evaluations will be required to examine TAND in relation to intellectual level and sex. In addition, efforts are underway to determine if there may be “natural TAND clusters” consisting of natural groupings of TAND characteristics within and between individuals with TSC across levels of TAND [7, 13]. The TOSCA cohort may provide a powerful dataset to examine this possibility further. In spite of the limitations inherent to a large-scale natural history study, results provide strong data to encourage clinicians to evaluate for neuropsychiatric comorbidity in all children and adults with TSC. The 2012 TSC surveillance and management guidelines recommend annual screening for TAND [34]. A simple tool called the TAND Checklist has been developed and validated in a pilot study that could provide easy guidance to healthcare professionals in assessing neuropsychiatric difficulties in each individual with TSC [3, 5, 6].
  37 in total

Review 1.  Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis.

Authors:  Petrus de Vries; Ayla Humphrey; Deborah McCartney; Penny Prather; Patrick Bolton; Ann Hunt
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-07       Impact factor: 4.785

Review 2.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

3.  Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex.

Authors:  C Joinson; F J O'Callaghan; J P Osborne; C Martyn; T Harris; P F Bolton
Journal:  Psychol Med       Date:  2003-02       Impact factor: 7.723

4.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

5.  Intellectual ability in tuberous sclerosis complex correlates with predicted effects of mutations on TSC1 and TSC2 proteins.

Authors:  Ho Tin Wong; Deborah L McCartney; Julia C Lewis; Julian R Sampson; Christopher J Howe; Petrus J de Vries
Journal:  J Med Genet       Date:  2015-09-25       Impact factor: 6.318

6.  Behavior problems in children with tuberous sclerosis complex and parental stress.

Authors:  Claudine M C Kopp; David A Muzykewicz; Brigid A Staley; Elizabeth A Thiele; Margaret B Pulsifer
Journal:  Epilepsy Behav       Date:  2008-07-07       Impact factor: 2.937

7.  Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex.

Authors:  David A Muzykewicz; Peter Newberry; Nicole Danforth; Elkan F Halpern; Elizabeth A Thiele
Journal:  Epilepsy Behav       Date:  2007-10-23       Impact factor: 2.937

8.  Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.

Authors:  Darcy A Krueger; Hope Northrup
Journal:  Pediatr Neurol       Date:  2013-10       Impact factor: 3.372

9.  TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex.

Authors:  John C Kingswood; Paolo Bruzzi; Paolo Curatolo; Petrus J de Vries; Carla Fladrowski; Christoph Hertzberg; Anna C Jansen; Sergiusz Jozwiak; Rima Nabbout; Matthias Sauter; Renaud Touraine; Finbar O'Callaghan; Bernard Zonnenberg; Stefania Crippa; Silvia Comis; Guillaume Beaure d'Augères; Elena Belousova; Tom Carter; Vincent Cottin; Maria Dahlin; José Carlos Ferreira; Alfons Macaya; Mirjana Perkovic Benedik; Valentin Sander; Sotirios Youroukos; Ramon Castellana; Bulent Ulker; Martha Feucht
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

10.  Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis.

Authors:  K Ridler; E T Bullmore; P J De Vries; J Suckling; G J Barker; S J Meara; S C Williams; P F Bolton
Journal:  Psychol Med       Date:  2001-11       Impact factor: 7.723

View more
  33 in total

1.  Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex.

Authors:  Bo Zhang; Dongjun Guo; Lirong Han; Nicholas Rensing; Akiko Satoh; Michael Wong
Journal:  Neurobiol Dis       Date:  2019-10-09       Impact factor: 5.996

2.  Diagnostic features of tuberous sclerosis complex: case report and literature review.

Authors:  Sultan Abdulwadoud Alshoabi; Abdullgabbar M Hamid; Fahad H Alhazmi; Abdulaziz A Qurashi; Osamah M Abdulaal; Khaled M Aloufi; Tareef S Daqqaq
Journal:  Quant Imaging Med Surg       Date:  2022-01

3.  Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study.

Authors:  Jamie K Capal; Marian E Williams; Deborah A Pearson; Robin Kissinger; Paul S Horn; Donna Murray; Kristn Currans; Bridget Kent; Martina Bebin; Hope Northrup; Joyce Y Wu; Mustafa Sahin; Darcy A Krueger
Journal:  Ann Neurol       Date:  2021-10-29       Impact factor: 10.422

4.  Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia.

Authors:  Todd Lencz; Jin Yu; Raiyan Rashid Khan; Erin Flaherty; Shai Carmi; Max Lam; Danny Ben-Avraham; Nir Barzilai; Susan Bressman; Ariel Darvasi; Judy H Cho; Lorraine N Clark; Zeynep H Gümüş; Joseph Vijai; Robert J Klein; Steven Lipkin; Kenneth Offit; Harry Ostrer; Laurie J Ozelius; Inga Peter; Anil K Malhotra; Tom Maniatis; Gil Atzmon; Itsik Pe'er
Journal:  Neuron       Date:  2021-03-22       Impact factor: 17.173

5.  Involvement of mental health professionals in the treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND): results of a multinational European electronic survey.

Authors:  Robert Waltereit; Guillaume Beaure d'Augères; Jasna Jancic; John Chris Kingswood; Maya Koleva; Ruben Marques; Vicente Villanueva; Stéphane Auvin
Journal:  Orphanet J Rare Dis       Date:  2021-05-12       Impact factor: 4.123

6.  Occlusal problems, mental health issues and non-carious cervical lesions.

Authors:  Bruna L Nascimento; Alexandre R Vieira; Mariana Bezamat; Sergio A Ignácio; Evelise M Souza
Journal:  Odontology       Date:  2021-09-27       Impact factor: 2.634

Review 7.  Molecular regulation of brain metabolism underlying circadian epilepsy.

Authors:  Felix Chan; Judy Liu
Journal:  Epilepsia       Date:  2021-01-04       Impact factor: 5.864

Review 8.  Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine.

Authors:  Susanne Schubert-Bast; Adam Strzelczyk
Journal:  Ther Adv Neurol Disord       Date:  2021-07-17       Impact factor: 6.570

9.  The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.

Authors:  Francesca Cervi; Veronica Saletti; Katherine Turner; Angela Peron; Sara Bulgheroni; Matilde Taddei; Francesca La Briola; Maria Paola Canevini; Aglaia Vignoli
Journal:  Orphanet J Rare Dis       Date:  2020-09-07       Impact factor: 4.123

10.  Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype.

Authors:  Petrus J de Vries; Elena Belousova; Mirjana P Benedik; Tom Carter; Vincent Cottin; Paolo Curatolo; Maria Dahlin; Lisa D'Amato; Guillaume Beaure d'Augères; José C Ferreira; Martha Feucht; Carla Fladrowski; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Ruben Marques; Rima Nabbout; Finbar O'Callaghan; Jiong Qin; Valentin Sander; Matthias Sauter; Seema Shah; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; John C Kingswood; Anna C Jansen
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.